Colgate-Palmolive Company (CL)
Colgate-Palmolive Swings to a Loss on Charges
Colgate-Palmolive swung to a loss in the fourth quarter, hurt by a large charge tied to its struggling skin-health business, but sales climbed despite what the company says is a difficult environment.
Colgate's Q4 Earnings Around the Corner: What Investors Should Know?
CL heads into Q4 earnings with pricing, innovation and productivity efforts supporting growth, while inflation, tariffs and volume softness weigh on margins.
Colgate-Palmolive (CL) Reports Next Week: What You Should Expect
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 “Forever Stocks” to Hold When the Market Won't Sit Still
With so much volatility in the market, it's a good time for investors to consider stocks that they can hold for the long haul. These compounders don't have to make up a large part of your portfolio, but they're good stocks to have for investors who like to step away from their screens.
Is Colgate's Cost Discipline Enough in a Softer Demand Cycle?
CL is leaning on productivity, AI and cost discipline to offset input inflation and protect margins amid uneven demand.
This Consumer-Products Giant's Stock Is a Wall Street Top Pick for 2026
Morgan Stanley analysts named a consumer products giant known for its toothpaste one of their top picks for the year.
Colgate-Palmolive: Consistent Long-Term Execution Makes It Attractive
Colgate-Palmolive (CL) is a Dividend King with strong dividend safety, high margins, and consistent long-term execution, currently trading at a reasonable 21.6x earnings. CL's science-based innovation and focus on high-growth categories and incremental product improvements, reinforcing its wide moat and market share, especially in oral care. Despite reduced guidance and sector headwinds, CL remains undervalued with a fair value estimate of $84.18 versus a ~$79 share price, supporting a buy rating.
Is Colgate's Productivity Program a Catalyst for Its Margins?
CL's productivity program is easing cost pressures and paving the way for mid-25% margins, balancing efficiency with brand investment.
4 Reasons Colgate-Palmolive Is a No-Brainer Hold Through 2027
Colgate-Palmolive NYSE: CL is a buy-and-hold quality stock offering significant incentives to consumer staples investors. The stock is trading at historically low valuations, pays a higher-than-average yield, can sustain its capital return, will grow its business in 2026, and buys back shares, to name a few.
Colgate-Palmolive Company (CL) Presents at Morgan Stanley Global Consumer & Retail Conference 2025 Transcript
Colgate-Palmolive Company (CL) Presents at Morgan Stanley Global Consumer & Retail Conference 2025 Transcript
Colgate-Palmolive: Wide Moat And A Mispriced Future
Colgate-Palmolive (CL)'s diverse category system creates a deeper moat than its simple products suggest. It shows how shared chemistry, manufacturing flexibility and retail presence strengthen its competitive position. Hill's provides a stabilising demand pattern that supports the broader portfolio especially during slowdowns.
Colgate-Palmolive: This Dividend King Is Rebounding (Technical Analysis)
Colgate-Palmolive (CL) is a Dividend King with a 62-year record of dividend growth and global dominance in oral care products. CL recently rebounded from a multi-year earnings decline, driven by its 2022 Global Productivity Initiative and renewed focus on growth businesses. Technical analysis shows institutional accumulation, with positive momentum signals and a breakout above resistance on strong volume.
